Skip to main content

Advertisement

SpringerLink
Log in

To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription

  • Editorial Commentary
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Within a short period, we have witnessed a dramatic increase in the use of mycophenolate mofetil (MMF) in pediatric renal transplantation, with the drug often replacing azathioprine in combination with calcineurin inhibitor therapy. When the drug was introduced, the manufacturer considered therapeutic drug monitoring (TDM) unnecessary. However, TDM studies revealed substantial inter- and intra-individual variability and drug interactions. There is a substantial drug interaction between MMF and cyclosporine, and lower doses are required in combination with tacrolimus (~500–800 mg/m2 per day) than with cyclosporine (~1,200 mg/m2 per day). Patients with autoimmune disease require an intermediate dose when receiving no concomitant calcineurin inhibitor (~900 mg/m2 per day). It has been possible to detect drug interactions and to minimize adverse events only with TDM. This is especially important with increasing use of combination therapies. Pharmacodynamic monitoring (measuring the biological response to a drug) coupled with pharmacokinetics allow optimization of drug dosing, with maximum efficacy and minimal toxicity. More work is required to establish specific target ranges with the various drug combinations—especially for the pediatric population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Boreus LO (1983) The role of therapeutic drug monitoring in childhood. Pediatr Pharmacol 3:145–148

    CAS  Google Scholar 

  2. Kahan BD, Ried M, Newburger J (1983) Pharmacokinetics of cyclosporine in human renal transplantation. Transplant Proc 15:446–453

    Google Scholar 

  3. Eugui EM, Mirkovich A, Allison A (1991) Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 33:175–183

    CAS  PubMed  Google Scholar 

  4. Schütz E, Shipkova M, Armstrong VW, Niedmann PD, Weber L, Tonshoff B, Pethig K, Wahlers T, Braun F, Ringe B, Ollerich M (1998) Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites. Transplant Proc 30:1185–1187

    Article  PubMed  Google Scholar 

  5. Sollinger HW (1995) Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60:225–232

    CAS  PubMed  Google Scholar 

  6. European Mycophenolate Mofetil Cooperative Study Group (1999) Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 68:391–396

    PubMed  Google Scholar 

  7. Johnson C, Ahsan N, Gonwa T, Halloran P, Stegall M, Hardy M, Metzger R, Shield C 3rd, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, Veldhuisen P van, Salm K, Tolzman D, Fitzsimmons WE (2000) Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 69:834–841

    CAS  PubMed  Google Scholar 

  8. Benfield MR, Symons JM, Bynon S, Eckhoff D, Herrin J, Harmon W, Kohaut E (1999) Mycophenolate mofetil in pediatric renal transplantation. Pediatr Transplant 3:33–37

    Article  CAS  PubMed  Google Scholar 

  9. Jungraithmayr T, Staskewitz A, Kirste G, Boswald M, Bulla M, Burghard R, Dippell J, Greiner C, Helmchen U, Klare B, Klaus G, Leichter HE, Mihatsch MJ, Michalk DV, Misselwitz J, Plank C, Querfeld U, Weber LT, Wiesel M, Tonshoff B, Zimmerhackl LB; For the German Pediatric Renal Transplantation Study Group (2003) Pediatric renal transplantation with mycophenolate mofetil-based immunosuppression without induction: results after three years. Transplantation. 75:454–461

    Google Scholar 

  10. Ettenger R, Menster B, Warshaw B, Potter D, Nichols A (1997) Mycophenolate mofetil (MMF) in pediatric (ped) renal transplantation (TX): final report of the pediatric MMF study group (PMMFSG) (abstract). Abstracts of the 16th Annual Meeting American Society of Transplant Physicians, abstract 287

  11. Weber LT, Shipkova M, Lamersdorf T, Niedmann PD, Wiesel M, Mandelbaum A, Zimmerhackl LB, Schutz E, Mehls O, Oellerich M, Armstrong VW, Tonshoff B (1998) Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 9:1511–1520

    CAS  PubMed  Google Scholar 

  12. Weber LT, Lamersdorf T, Shipkova M, Niedmann PD, Wiesel M, Zimmerhackl LB, Staskewitz A, Schutz E, Mehls O, Oellerich M, Armstrong VW, Tonshoff B (1999) Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit 21:498–506

    Article  CAS  PubMed  Google Scholar 

  13. Zucker K, Rosen A, Tsaroucha A, Faria L de, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J (1997) Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 5:225–232

    Article  CAS  PubMed  Google Scholar 

  14. Hubner GI, Eismann R, Sziegoleit W (1999) Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit 21:536–539

    Article  CAS  PubMed  Google Scholar 

  15. Filler G, Lampe D, Mai I, Strehlau J, Ehrich JHH (1998) Reduced dosing of MMF in combination with tacrolimus for steroid resistant, vascular rejection in renal allografts. Transpl Int 11 [Suppl 1]:82–85

    Google Scholar 

  16. Filler G, Zimmering M, Mai I (2000) Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 14:100–104

    Article  CAS  PubMed  Google Scholar 

  17. Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A, Miller J (1999) Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 21:35–43

    Article  CAS  PubMed  Google Scholar 

  18. Pou L, Brunet M, Cantarell C, Vidal E, Oppenheimer F, Monforte V, Vilardell J, Roman A, Martorell J, Capdevila L (2001) Mycophenolic acid plasma concentrations: influence of comedication. Ther Drug Monit 23:35–38

    Article  CAS  PubMed  Google Scholar 

  19. Mourad M, Malaise J, Chaib Eddour D, De Meyer M, Konig J, Schepers R, Squifflet JP, Wallemacq P (2001) Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem 47:1241–1248

    CAS  PubMed  Google Scholar 

  20. Filler G, Hansen M, LeBlanc C, Lepage N, Franke D, Mai I, Feber J (2003) Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. Pediatr Nephrol 18:445–449

    Article  PubMed  Google Scholar 

  21. Filler G, Lepage N, Delisle B, Mai I (2001) Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients. Ther Drug Monit 23:514–519

    Article  CAS  PubMed  Google Scholar 

  22. Pape L, Froede K, Strehlau J, Ehrich JH, Offner G (2003) Alterations of cyclosporin A metabolism induced by mycophenolate mofetil. Pediatr Transplant 7:302–304

    Article  CAS  PubMed  Google Scholar 

  23. Kovarik JM, Hoyer PF, Ettenger R, Punch J, Soergel M (2003) Cyclosporine absorption profiles in pediatric kidney and liver transplant patients. Pediatr Nephrol 18:1275–1279

    Article  CAS  PubMed  Google Scholar 

  24. Hubner GI, Eismann R, Sziegoleit W (2000) Relationship between mycophenolate mofetil side effects and mycophenolic acid plasma trough levels in renal transplant patients. Arzneimittelforschung 50:936–940

    CAS  PubMed  Google Scholar 

  25. Jacqz-Aigrain E, Khan Shaghaghi E, Baudouin V, Popon M, Zhang D, Maisin A, Loirat C (2000) Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. Pediatr Nephrol 14:95–99

    Article  CAS  PubMed  Google Scholar 

  26. David-Neto E, Pereira Araujo LM, Sumita NM, Mendes ME, Ribeiro Castro MC, Alves CF, Kakehashi E, Romano P, Yagyu EM, Queiroga M, Nahas WC, Ianhez LE (2003) Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. Pediatr Nephrol 18:266–272

    PubMed  Google Scholar 

  27. Cattaneo D, Gaspari F, Ferrari S, Stucchi N, Del Priore L, Perico N, Gotti E, Remuzzi G (2001) Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant 15:402–409

    Article  CAS  PubMed  Google Scholar 

  28. Gallagher H, Andrews PA (2001) Cytomegalovirus infection and abdominal pain with mycophenolate mofetil: is there a link? Drug Saf 24:405–412

    CAS  PubMed  Google Scholar 

  29. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, Zimmerhackl LB, Oellerich M, Tonshoff B (2002) The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol. 13:759–768

    Google Scholar 

  30. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, Zimmerhackl LB, Oellerich M, Tonshoff B (2002) Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem 48:517–525

    CAS  PubMed  Google Scholar 

  31. Langman LJ, LeGatt DF, Yatscoff RW (1995) Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity. Clin Chem 41:295–299

    CAS  PubMed  Google Scholar 

  32. Budde K, Glander P, Bauer S, Braun K, Waiser J, Fritsche L, Mai I, Roots I, Neumayer HH (2000) Pharmacodynamic monitoring of mycophenolate mofetil. Clin Chem Lab Med 38:1213–1216

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The editorial review of the manuscript by Darlene Poulin is greatly appreciated.

Author information

Authors and Affiliations

  1. Division of Pediatric Nephrology, Children’s Hospital of Eastern Ontario, Ottawa University, 401 Smyth Road, Ottawa, Ontario, K1H 8L1, Canada

    Guido Filler

  2. Department of Laboratory Medicine and Pathology, Children’s Hospital of Eastern Ontario, Ottawa University, 401 Smyth Road, Ottawa, Ontario, K1H 8L1, Canada

    Nathalie Lepage

Authors
  1. Guido Filler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nathalie Lepage
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guido Filler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Filler, G., Lepage, N. To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription. Pediatr Nephrol 19, 962–965 (2004). https://doi.org/10.1007/s00467-004-1571-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-004-1571-4

Keywords

Search

Navigation